Illinois health care providers may no longer order the monoclonal antibodies bamlanivimab and etesevimab until further notice due to rising prevalence in Illinois of the SARS-CoV-2 P.1 variant, which is not susceptible to the combination therapy, the Office of the Assistant Secretary for Preparedness and Response announced Friday.

The Food and Drug Administration recommends Illinois providers use the alternative monoclonal antibody therapy REGEN-COV, which is likely to remain active against the variant, ASPR said. The announcement does not affect other states, but providers should monitor the frequency of the P.1 variant in their region and review the fact sheets for each authorized monoclonal antibody therapy for details regarding specific variants and resistance, ASPR said.

Related News Articles

Headline
The Health Resources and Services Administration today awarded 14 organizations grants to hire people to support COVID-19 vaccination and outreach in…
Headline
The Food and Drug Administration Friday authorized for emergency use two batches of drug substance manufactured for the Janssen (Johnson & Johnson)…
Headline
Novavax today announced phase 3 trial results for its COVID-19 vaccine, saying it provides 100% protection against moderate and severe disease, with a 90.…
Headline
The Centers for Disease Control and Prevention is asking jurisdictions to distribute portions of their COVID-19 vaccine allocations to enable administration at…
Headline
Johnson & Johnson today said the Food and Drug Administration agreed to extend the expiration date for its COVID-19 vaccine by six weeks. The move means…
Headline
During the COVID-19 pandemic, Grand Rapids, Mich-based Spectrum Health used the full scope of its resources to enable easy vaccine access, keep its communities…